Cepheid recently developed a new TB cartridge known as Xpert MTB/XDR assay with in-built system of quality controls that can detect resistance-conferring mutations to Isoniazid (inhA promoter, katG, fabG1, oxyR-aphC intergenic region), and second-line drugs: ethionamide (inhA promoter), Fluoroquinolone resistance-associated mutations in the gyrA and gyrB quinolone resistance determining regions (QRDR), and second-line injectable drugs (Amikacin, Kanamycin, and Capreomycin) associated mutations in the rrs gene and the eis promoter region [10, 11]. Here, INHA is linked to tuberculosis.